Insmed CEO Geoffrey Allan Testifies at Congressional Hearing

    At U.S. House Oversight Committee Discussing the Need for a "Generic
Pathway" for Biologics, Dr. Allan Discusses the Role of Biotech Companies

    RICHMOND, VA., March 26 /CNW/ - Insmed, Inc. (NASDAQ:  INSM) President and
Chief Executive Officer, Geoffrey Allan, Ph. D., testified today at a
congressional hearing, "Safe and Affordable Biotech Drugs - The Need for a
Generic Pathway."

    Dr. Allan was a witness before the House of Representatives Oversight and
Government Reform Committee Majority Staff hearing. He, along with other
industry and regulatory experts, shared his views on the role of biotech
companies in the debate on the need for a generic pathway for biologics.
Currently, the FDA lacks clear authority to approve a generic form of a
biologic medication.

    Biologics comprise one of the fastest growing and most expensive
categories of drugs. By 2009, sales are estimated to reach $90 billion. Many
biopharmaceutical drugs are already off patent or will come off-patent,
allowing for a generic pathway to create biologics. According to published
reports, an estimated $10 billion worth of biopharmaceutical drugs are
expected to come off patent by 2010.

    In his testimony, Dr. Allan stated, "Insmed has developed significant
intellectual capital focused towards protein characterization and
purification. We have invested in building the facilities required to
manufacture quality proteins...The combination of our proprietary protein
platform with a biogeneric protein platform meets our goal to sustain
innovation along with the ability to provide safe and affordable drugs to
address a growing economic issue."

    He added, "The science has reached a level of sophistication to make this
endeavour entirely possible, all we need now is the regulatory go ahead."

    It is Dr. Allan's belief that once legislation comes into effect, Insmed
will be well positioned to be a key player in the generic biologics market,
given the Company's expertise.

    A full transcript of Dr. Allan's testimony is available on the Insmed web

    About Insmed Incorporated

    Insmed is a biopharmaceutical company focused on the development and
commercialization of drug candidates for the treatment of metabolic diseases
and endocrine disorders with unmet medical needs.

    The company's leading product, IPLEX(TM), is currently in clinical trials
for Myotonic Muscular Dystrophy, the most common form of adult-onset muscular

    It is also in devlopment for HIV associated Adipose Redistribution
Syndrome (HARS). IPLEX was approved as an orphan drug by the United States
Food and Drug Administration in December 2005 for the treatment of growth
failure in children with severe primary IGF-I deficiency (Primary IGFD) or
with growth hormone (GH) gene deletion who have developed neutralizing
antibodies to GH. For more information, please visit

    Statements included within this press release, which are not historical
in nature, may constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are not limited
to, statements regarding planned clinical trial design, our regulatory and
business strategies, plans and objectives of management and growth
opportunities for existing or proposed products. Such forward-looking
statements are subject to numerous risks and uncertainties, including risks
that product candidates may fail in the clinic or may not be successfully
marketed or manufactured, the company may lack financial resources to complete
development of product candidates, the FDA may interpret the results of our
studies differently than we have, competing products may be more successful,
demand for new pharmaceutical products may decrease, the biopharmaceutical
industry may experience negative market trends and other risks detailed from
time to time in the company's filings with the Securities and Exchange
Commission. As a result of these and other risks and uncertainties, actual
results may differ materially from those described in this press release. For
further information with respect to factors that could cause actual results to
differ from expectations, reference is made to reports filed by the Company
with the Securities and Exchange Commission under the Securities Exchange Act
of 1934, as amended. The forward-looking statements made in this release are
made only as of the date hereof and Insmed disclaims any intention or
responsibility for updating predictions or financial guidance contained in
this release.

For further information:

For further information: Insmed, Incorporated Jody M. Lomenzo, Director,
Corporate Communications, 804-565-3056; or IRI Investor
Relations Haris Tajyar, Investor Relations, 818-382-9702

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890